TY - JOUR AU - Kim, Ji-Yeon AU - Park, Seri AU - Im, Seock-Ah AU - Kim, Sung-Bae AU - Sohn, Joohyuk AU - Lee, Keun Seok AU - Chae, Yee Soo AU - Lee, Ki Hyeong AU - Kim, Jee Hyun AU - Im, Young-Hyuck AU - Kim, Tae-Yong AU - Lee, Kyung-Hun AU - Ahn, Jin-Hee AU - Kim, Gun Min AU - Park, In Hae AU - Lee, Soo Jung AU - Han, Hye Sook AU - Kim, Se Hyun AU - Jung, Kyung Hae AU - Park, Yeon Hee AU - Korean Cancer Study Group PY - 2019 DA - 2019/05/28 TI - Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11) JO - Cancer Communications SP - 29 VL - 39 IS - 1 AB - A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). SN - 2523-3548 UR - https://doi.org/10.1186/s40880-019-0375-7 DO - 10.1186/s40880-019-0375-7 ID - Kim2019 ER -